Skip to main content
. 2020 Mar 14;4(4):586–593. doi: 10.1002/rth2.12316

Table 3.

Predictors of therapy nonadherence in MONDOAC

  Adherent Nonadherent OR (95% CI) ORa (95% CI)
>75 y 568 (92) 46 (8) Reference Reference
60‐75 y 507 (83) 107 (17) 2.6 (1.8‐3.8) 2.5 (1.8‐3.7)
<60 y 74 (67) 36 (33) 6.0 (3.7‐9.9) 5.9 (3.6‐9.8)
Female 471 (90) 55 (10) Reference Reference
Male 667 (83) 133 (17) 1.7 (1.2‐2.4) 1.7 (1.2‐2.4)
Low education 480 (93) 37 (7) Reference Reference
High education 356 (78) 102 (22) 3.7 (2.5‐5.6) 2.9 (1.9‐4.4)
Time on VKA before switch ≥2 y 823 (87) 119 (13) Reference Reference
Time on VKA before switch <2 y 328 (83) 68 (17) 1.4 (1.0‐2.0) 1.26 (0.9‐1.7)
INR control ≤ monthly 459 (87) 71 (13) Reference Reference
INR control ≥ weekly 235 (81) 55 (19) 1.5 (1.0‐2.2) 1.5 (1.0‐2.2)
Comorbidity 881 (88) 116 (12) Reference Reference
No comorbidity 263 (79) 68 (21) 2.0 (1.4‐2.7) 1.5 (1.1‐2.2)
Consultation with MS ≥ once/year 465 (88) 61 (12) Reference Reference
Consultation with MS < once/year 563 (83) 113 (17) 1.5 (1.1‐2.1) 1.6 (1.1‐2.2)
No history of minor bleeding events on DOAC 940 (87) 140 (13) Reference Reference
History of minor bleeding events on DOAC 233 (83) 49 (17) 1.4 (1.0‐2.0) 1.9 (1.3‐2.8)
Switching own initiative 246 (86) 39 (14) Reference Reference
Switching advice of physician 857 (86) 144 (14) 1.1 (0.7‐1.6) 1.1 (0.7‐1.6)
DOAC once daily 534 (89) 65 (11) Reference Reference
DOAC twice daily 634 (84) 124 (16) 1.6 (1.2‐2.2) 1.9 (1.3‐2.6)

Continuous variable denoted as mean (standard deviation), categorical variables as number (percentage).

DOAC, direct oral anticoagulant; INR, International Normalized Ratio; MONDOAC, Monitoring of direct oral anti‐coagulant; MS, medical specialist; VKA, vitamin K antagonist.

a

Adjusted for age and sex (where applicable).